Mycrodose Therapeutics is widely recognized as the first company to bring Advanced Drug Delivery Technologies (ADD) into the Psychedelic Medicine Sector. "The confidence shown by investors regarding ...
HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function, ...
San Diego, California--(Newsfile Corp. - May 10, 2022) - Mycrodose Therapeutics showed the ability to synthesize and stabilize psilocin in their laboratory for use in their IP-protected drug delivery ...
VANCOUVER, BC, Oct. 19, 2021 /PRNewswire/ - October 19, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global ...
San Diego, California--(Newsfile Corp. - March 31, 2022) - Mycrodose Therapeutics ('Mycrodose'), a leading US pharmaceutical company specializing in the development of advanced drug delivery ...
Mycrodose Therapeutics successfully closes oversubscribed seven-figure financing round. Financing was funded by multiple high profile institutional investors, VCs, and Psychedelic Funds, including; ...
Mycrodose Therapeutics successfully closes oversubscribed seven-figure financing round. Financing was funded by multiple high profile institutional investors, VCs, and Psychedelic Funds, including; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback